Equities

Rockwell Medical Inc

Rockwell Medical Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)2.20
  • Today's Change-0.13 / -5.58%
  • Shares traded127.00
  • 1 Year change+15.79%
  • Beta1.4182
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Rockwell Medical, Inc. is a healthcare company. The Company develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers around the world. The Company operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. It is the supplier of life-sustaining hemodialysis concentrates products to dialysis clinics. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. The Company manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa.

  • Revenue in USD (TTM)98.92m
  • Net income in USD-1.24m
  • Incorporated2019
  • Employees237.00
  • Location
    Rockwell Medical Inc30142 WIXOM ROADWIXOM 48393United StatesUSA
  • Phone+1 (248) 960-9009
  • Fax+1 (302) 655-5049
  • Websitehttps://www.rockwellmed.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Odonate Inc0.00-102.07m49.87m137.00--1,839.01-----13.59-13.590.009.270.00----0.00-66.98-58.36-83.00-65.14------------0.00-------12.99------
BGM Group Ltd29.87m-7.86m50.59m298.00--1.15--1.69-1.10-1.104.186.070.52373.7325.96100,236.40-14.432.71-17.013.862.9211.66-27.562.726.06-0.75270.0026.11-28.35-1.60-822.64--12.86--
Aadi Bioscience Inc25.07m-61.69m56.20m53.00--0.8149--2.24-2.29-2.290.92852.800.22250.6964.09281,685.40-54.75-50.25-65.27-56.1587.39---246.06-473.974.54--0.00--60.063.85-8.68--153.54--
bluebird bio Inc53.12m-300.52m57.77m375.00------1.09-1.84-1.840.3039-0.02980.09852.034.42141,653.30-55.72-34.75-96.37-40.84-43.49-124.35-565.74-5,770.410.3272-13.371.03--720.04-11.588.00---30.47--
OptiNose Inc75.67m-31.15m59.56m132.00------0.787-0.2216-0.22160.5416-0.27250.65120.76592.96573,272.80-26.80-48.25---98.9590.2186.96-41.16-131.660.7198-1.611.48---6.9358.6452.58---27.96--
Cellectar Biosciences Inc0.00-49.67m64.10m20.00--41.37-----1.67-1.670.000.40790.00----0.00-168.84-83.69-450.38-99.80------------0.00-------32.80--17.55--
Hongchang International Co Ltd5.42m-208.79k66.15m8.00--1.63--12.21-0.0004-0.00040.01040.07840.09915.5037.20---0.2731-7.98-0.2965-10.944.5111.47-2.76-64.884.64--0.3169--3,289.22---42.63------
Global Pharmatech Inc.3.18m-2.24m67.19m217.00--0.4959--21.13-0.0964-0.09640.13670.34280.22921.593.5714,649.77-16.44---22.55--46.21---71.75--1.62-9.870.2223--32.43---142.03------
CASI Pharmaceuticals Inc22.06m-30.97m70.36m176.00--5.08--3.19-2.23-2.231.591.030.320.92652.03125,312.50-43.04-34.75-66.19-46.9154.3155.98-134.50-153.722.32--0.58---21.41--34.27--14.65--
Rockwell Medical Inc98.92m-1.24m71.10m237.00--2.4449.860.7188-0.0496-0.04963.230.90151.8014.4510.84417,371.30-2.25-46.29-3.34-65.3816.914.66-1.25-36.512.000.31940.2654--14.845.6954.82--76.21--
Journey Medical Corp57.77m-18.34m77.43m58.00--9.87--1.34-0.9276-0.92762.930.52710.8892.166.19996,051.80-28.22---76.21--57.32---31.74--1.03-13.650.6582--7.48--87.00------
I-Mab ADR-100.00bn-100.00bn77.57m220.00--0.33----------2.91-----------35.51---41.43-------509.54----0.00--111.86-13.6544.45---5.95--
Zhong Yuan Bio-Technology Holdings Ltd2.49m232.02k88.37m35.00391.37348.44--35.440.0128-0.01760.13950.01430.8583-1.613.2571,253.436.49--19.10--106.30--7.57--0.83092.530.8593---28.60---148.37------
Assertio Holdings Inc125.76m-68.49m92.07m53.00--0.7056--0.7321-0.7212-0.72121.321.370.38340.90522.342,372,887.00-20.88-21.51-30.33-32.0570.3188.68-54.46-62.101.57--0.2293---2.67-13.38-402.80---28.25--
Data as of Nov 21 2024. Currency figures normalised to Rockwell Medical Inc's reporting currency: US Dollar USD

Institutional shareholders

24.34%Per cent of shares held by top holders
HolderShares% Held
Armistice Capital LLCas of 30 Sep 20243.58m11.54%
The Vanguard Group, Inc.as of 30 Sep 20241.19m3.85%
GlobeFlex Capital LPas of 30 Sep 2024743.26k2.40%
Marshall Wace LLPas of 30 Sep 2024508.67k1.64%
Perkins Capital Management, Inc.as of 30 Sep 2024350.38k1.13%
Geode Capital Management LLCas of 30 Sep 2024307.29k0.99%
Richmond Brothers, Inc.as of 30 Sep 2024249.87k0.81%
Columbia Management Investment Advisers LLCas of 30 Sep 2024222.34k0.72%
BlackRock Fund Advisorsas of 30 Sep 2024216.63k0.70%
EAM Investors LLCas of 30 Sep 2024178.74k0.58%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.